Robert W. Baird Increases Revvity (NYSE:RVTY) Price Target to $127.00

Revvity (NYSE:RVTY) had its price objective hoisted by Robert W. Baird from $126.00 to $127.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 23.78% from the company’s previous close.

A number of other analysts have also recently commented on RVTY. Barclays boosted their price target on Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Stifel Nicolaus boosted their price target on Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. Evercore ISI raised Revvity from an “in-line” rating to an “outperform” rating and boosted their price target for the stock from $88.00 to $125.00 in a research report on Thursday, January 4th. UBS Group cut Revvity from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $105.00 to $125.00 in a research report on Tuesday, January 16th. Finally, TD Cowen boosted their price target on Revvity from $123.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $118.17.

Revvity Stock Performance

Revvity stock opened at $102.60 on Tuesday. The stock’s 50 day simple moving average is $104.70 and its two-hundred day simple moving average is $101.32. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.77 and a current ratio of 2.23. The stock has a market cap of $12.67 billion, a price-to-earnings ratio of 84.79, a PEG ratio of 2.73 and a beta of 1.09. Revvity has a fifty-two week low of $79.50 and a fifty-two week high of $132.54.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Monday, April 29th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.04. The business had revenue of $649.90 million for the quarter, compared to analysts’ expectations of $646.83 million. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The business’s revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.01 EPS. As a group, analysts expect that Revvity will post 4.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Revvity

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the completion of the sale, the insider now directly owns 92,801 shares in the company, valued at approximately $9,677,288.28. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Revvity

A number of hedge funds have recently added to or reduced their stakes in the stock. Byrne Asset Management LLC purchased a new stake in shares of Revvity in the 4th quarter worth $1,112,000. State of Michigan Retirement System bought a new position in Revvity in the 4th quarter worth $3,688,000. Gulf International Bank UK Ltd bought a new position in Revvity in the 4th quarter worth $1,136,000. State of Alaska Department of Revenue bought a new position in Revvity in the 4th quarter worth $1,456,000. Finally, International Assets Investment Management LLC bought a new position in Revvity in the 4th quarter worth $1,278,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.